Compound News and Research

RSS

Update from Karo Bio for the period January-September

In an update of the project portfolio, Karo Bio announced, among other things, that the company, in accordance with earlier communicated plans, has submitted an IND application for eprotirome to the American Food and Drug Administration (FDA); that a candidate drug has been nominated within the ER-beta program; and that the company has decided not to initiate further in-house development of KB3305 for the treatment of type 2 diabetes.

22 Oct 2009

GeckoSystems to discuss its sensor fusion based vision system

GeckoSystems Intl. Corp. (http://www.geckosystems.com/) -- announced today that during their first annual "Mobile Robots in Motion" conference November 4-5, 2009 attendees will be able to observe and discuss GeckoSystems' sensor fusion based vision system, the CompoundSensorArray™.

22 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

NicOx reports financial results for the first nine months of 2009

NicOx S.A. today reported financial results for the nine months ended September 30, 2009.

22 Oct 2009

Exposure to stress hormones and chemicals while in the womb can affect male fertility

Exposure to a combination of excess stress hormones and chemicals while in the womb could affect a man's fertility in later life, a study suggests.

22 Oct 2009

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

U.S. Pharmacopeial fellowships awarded to 6 students

New research focused on the quality of key medicines and their use as well as increasingly popular botanicals is being sponsored by the U.S. Pharmacopeial (USP) Convention under its 2009� Fellowship Program.

21 Oct 2009

OXIS International retains Quinn Emanuel Urquhart Oliver & Hedges to enforce all patents related to L-Ergothioneine

OXIS INTERNATIONAL, INC. announced today that the Company has retained Quinn Emanuel Urquhart Oliver & Hedges (“Quinn Emanuel”) to enforce all patents related to the unique benefits of its potent antioxidant compound L-Ergothioneine (“ERGO”).

21 Oct 2009

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Wellstat Therapeutics Corporation and sanofi-aventis announced today a global licensing agreement to develop, manufacture and commercialize PN2034, a first-in-class oral insulin sensitizer for the treatment of Type II diabetes.

21 Oct 2009

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Most Canadians living with CKD have likely never spoken with their physicians about calcium and the serious health risks associated with its overuse. This is why Improving Patient Advocacy in Chronic Kidney Disease (ImPACKD), a group of CKD patients and caregivers committed to raising awareness about the risks of calcium overuse, is starting the conversation about the importance of knowing the limits and keeping them in check.

20 Oct 2009

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the first oral diagnostic test approved for growth hormone deficiency (GHD). Macimorelin is the International Non-proprietary Name (INN) designated for the compound by the World Health Organization (WHO).

19 Oct 2009

Mcconnell: GOP will seek amendments to offset cost of Medicare physician pay fix

"U.S. Senate Minority Leader Mitch McConnell, R-Ky., told reporters Thursday that Senate Republicans will offer amendments to offset the cost of a 10-year, $247 billion Medicare physician payment bill set for debate next week," according to The Wall Street Journal. The GOP amendments, he said, would "either pay for a one-year fix for Medicare physician payment rates - set to drop 21% in January - or a 10-year fix, possibly paid for with unused funds from the $787 billion fiscal stimulus measure passed earlier this year."

19 Oct 2009

Discovery may yield better understanding of protective gut-dwelling bacteria

Medical researchers have long suspected that obscure bacteria living within the intestinal tract may help keep the human immune system in balance. An international collaboration co-led by scientists at NYU Langone Medical Center has now identified a bizarre-looking microbial species that can single-handedly spur the production of specialized immune cells in mice.

19 Oct 2009

IL-2 compound ineffective against HIV-AIDS

An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped.

19 Oct 2009

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

Novel HIV drug to be studied in cell cultures and patients

A $6 million, five-year federal grant to The Children's Hospital of Philadelphia Research Institute will enable researchers to investigate a novel approach in treating HIV infection---a unique class of drugs focused on developing therapies for psychological and neurological effects in AIDS.

19 Oct 2009

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming.

19 Oct 2009

Multi-million dollar cooperative agreement for SMA drug development program

Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS).

19 Oct 2009

New range of foods from marine animals and plants to help fight human diseases

Milk drinks that lower blood pressure, meat products that reduce the risk of heart disease, chocolate that calms you down and a new range of foods that can fight obesity can be created from marine animals and plants. Japan already has several product ranges on the shelves and research programmes are underway all over the world to create more.

15 Oct 2009

Resveratrol in red grapes offers some protection against diabetes

A naturally produced molecule called resveratrol, found in the skin of red grapes, has been shown to lower insulin levels in mice when injected directly into the brain, even when the animals ate a high-fat diet.

15 Oct 2009

Compound News and Research

Update from Karo Bio for the period January-September

GeckoSystems to discuss its sensor fusion based vision system

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

NicOx reports financial results for the first nine months of 2009

Exposure to stress hormones and chemicals while in the womb can affect male fertility

Oxygen Biotherapeutics announces its expanded product development plan

U.S. Pharmacopeial fellowships awarded to 6 students

OXIS International retains Quinn Emanuel Urquhart Oliver & Hedges to enforce all patents related to L-Ergothioneine

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

Mcconnell: GOP will seek amendments to offset cost of Medicare physician pay fix

Discovery may yield better understanding of protective gut-dwelling bacteria

IL-2 compound ineffective against HIV-AIDS

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Novel HIV drug to be studied in cell cultures and patients

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Multi-million dollar cooperative agreement for SMA drug development program

New range of foods from marine animals and plants to help fight human diseases

Resveratrol in red grapes offers some protection against diabetes

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News